Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Co Ltd.BHVN · Entity 123269 | Director | January 22, 2020 | January 24, 2020 |
| Biomea Fusion, Inc.BMEA · Entity 6606 | Director | June 10, 2026 | June 12, 2026 |
| BridgeBio Pharma, Inc.BBIO · Entity 3360 | Director | June 22, 2026 | June 24, 2026 |
| Eidos Therapeutics, Inc.EIDX · Entity 143355 | Director | May 27, 2020 | May 29, 2020 |
| Invitae CorpNVTA · Entity 95935 | Director | April 27, 2023 | May 01, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Biohaven Pharmaceutical Holding Co Ltd.
Report date January 22, 2020 · Filed January 24, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | IndirectBy Spouse | 2,021 |
Reported balance
After 2020-01-22 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2020-01-22 · Exercise / conversion · Acquired 771 · Balance 2,021 F1: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse. |
| Common SharesSEC Table I · non-derivative | IndirectBy Spouse | 3,271 |
Reported balance
After 2020-01-22 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2020-01-22 · Exercise / conversion · Acquired 1,250 · Balance 3,271 F1: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse. |
| Common SharesSEC Table I · non-derivative | IndirectBy Spouse | 2,771 |
Reported balance
After 2020-01-22 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2020-01-22 · Sale · Disposed 500 · Balance 2,771 F1: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.38 - $55.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. |
| Common SharesSEC Table I · non-derivative | IndirectBy Spouse | 2,271 |
Reported balance
After 2020-01-22 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2020-01-22 · Sale · Disposed 500 · Balance 2,271 F1: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.39 - $56.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. |
| Common SharesSEC Table I · non-derivative | IndirectBy Spouse | 1,600 |
Reported balance
After 2020-01-22 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2020-01-22 · Sale · Disposed 671 · Balance 1,600 F1: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.41 - $57.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. |
| Common SharesSEC Table I · non-derivative | IndirectBy Spouse | 1,400 |
Reported balance
After 2020-01-22 transaction · row 6
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 6 · 2020-01-22 · Sale · Disposed 200 · Balance 1,400 F1: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.70 - $58.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. |
| Common SharesSEC Table I · non-derivative | IndirectBy Spouse | 1,250 |
Reported balance
After 2020-01-22 transaction · row 7
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 7 · 2020-01-22 · Sale · Disposed 150 · Balance 1,250 F1: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.70 - $59.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.54 · Expires 2027-09-04 | IndirectBy Spouse | 2,500 |
Reported balance
After 2020-01-22 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-01-22 · Exercise / conversion · Disposed 1,250 · Balance 2,500 F1: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse. F7: The option, representing a right to purchase a total of 5,000 shares was granted on September 5, 2017, vesting in four equal installments on September 5, 2018, 2019, 2020 and 2021, subject to the option holder's continuous service with the Issuer at each vesting date. The optionholder previously exercised the option with respect to 1,250 shares on November 22, 2019. F8: This employee stock option is held by the Reporting Person's spouse. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.42 · Expires 2028-11-19 | IndirectBy Spouse | 22,500 |
Reported balance
After 2020-01-22 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-01-22 · Exercise / conversion · Disposed 771 · Balance 22,500 F1: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse. F9: The option, representing a right to purchase a total of 30,000 shares was granted on November 20, 2018, vesting in four equal installments on November 20, 2019, 2020, 2021 and 2022, subject to the option holder's continuous service with the Issuer at each vesting date. The optionholder previously exercised the option with respect to 6,729 shares on November 20, 2019. F8: This employee stock option is held by the Reporting Person's spouse. |
Filing footnotes · ownership attribution and instrument terms
F1: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.38 - $55.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.39 - $56.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.41 - $57.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.70 - $58.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.70 - $59.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
F7: The option, representing a right to purchase a total of 5,000 shares was granted on September 5, 2017, vesting in four equal installments on September 5, 2018, 2019, 2020 and 2021, subject to the option holder's continuous service with the Issuer at each vesting date. The optionholder previously exercised the option with respect to 1,250 shares on November 22, 2019.
F8: This employee stock option is held by the Reporting Person's spouse.
F9: The option, representing a right to purchase a total of 30,000 shares was granted on November 20, 2018, vesting in four equal installments on November 20, 2019, 2020, 2021 and 2022, subject to the option holder's continuous service with the Issuer at each vesting date. The optionholder previously exercised the option with respect to 6,729 shares on November 20, 2019.
Biomea Fusion, Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.15 · Expires 2036-06-09 | Direct | 196,299 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 196,299 · Balance 196,299 F1: The shares underlying the stock option will vest in full upon the earlier of (i) the one-year anniversary of the date of grant or (ii) immediately prior to the annual meeting of the Issuer's stockholders that occurs following the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the stock option will vest in full upon the earlier of (i) the one-year anniversary of the date of grant or (ii) immediately prior to the annual meeting of the Issuer's stockholders that occurs following the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date.
BridgeBio Pharma, Inc.
Report date June 22, 2026 · Filed June 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,579 |
Reported balance
After 2026-06-22 transaction · row 1
1 source rowRow 1 · 2026-06-22 · Grant · Acquired 3,990 · Balance 10,579 F1: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date. F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.92 · Expires 2036-06-21 | Direct | 5,277 |
Reported balance
After 2026-06-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-22 · Grant · Acquired 5,277 · Balance 5,277 F3: The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F3: The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
Eidos Therapeutics, Inc.
Report date May 27, 2020 · Filed May 29, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.51 · Expires 2030-05-27 | Direct | 21,528 |
Reported balance
After 2020-05-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-05-27 · Grant · Acquired 21,528 · Balance 21,528 F1: The shares subject to this option shall vest and become exercisable in a single installment on the earlier of (i) the first anniversary of the grant date, so that all of the underlying shares shall be vested on May 26, 2021, or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service with the Issuer through the vesting date. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2018 Stock Option and Incentive Plan, as amended). |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest and become exercisable in a single installment on the earlier of (i) the first anniversary of the grant date, so that all of the underlying shares shall be vested on May 26, 2021, or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service with the Issuer through the vesting date. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2018 Stock Option and Incentive Plan, as amended).
Invitae Corp
Report date April 27, 2023 · Filed May 01, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 125,322 |
Reported balance
After 2023-04-27 transaction · row 1
1 source rowRow 1 · 2023-04-27 · Grant · Acquired 70,422 · Balance 125,322 F1: Shares issuable upon settlement of a restricted stock unit award that vests in full on May 15, 2024, subject to continued service with the Issuer through the vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.36 · Expires 2033-04-27 | Direct | 28,901 |
Reported balance
After 2023-04-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-04-27 · Grant · Acquired 28,901 · Balance 28,901 F2: Option vests in twelve equal monthly installments starting from April 27, 2023, subject to continued service with the Issuer through the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares issuable upon settlement of a restricted stock unit award that vests in full on May 15, 2024, subject to continued service with the Issuer through the vesting date.
F2: Option vests in twelve equal monthly installments starting from April 27, 2023, subject to continued service with the Issuer through the applicable vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 22, 2026 Filed Jun 24, 2026 22:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (Right to Buy) · Derivative | 5,277 | $0.00 Strike: $68.92 | $0.00 |
DisclosureSEC source: 0001470831-26-000632 · wk-form4_1782338761.xml · derivative · entry 2 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,277 Underlying: Common Stock · 5,277 shares Expires 2036-06-21 F3 · derivative.exercise_date: The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 22:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantCommon Stock | 3,990 | $0.00 | $0.00 |
DisclosureSEC source: 0001470831-26-000632 · wk-form4_1782338761.xml · nonDerivative · entry 1 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,579 F1 · kind: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 20:15 UTC | Biomea Fusion, Inc. BMEA · Entity 6606 | GrantStock Option (Right to Buy) · Derivative | 196,299 | $0.00 Strike: $1.15 | $0.00 |
DisclosureSEC source: 0001193125-26-269469 · ownership.xml · derivative · entry 1 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 196,299 Underlying: Common Stock · 196,299 shares Expires 2036-06-09 F1 · derivative.exercise_date: The shares underlying the stock option will vest in full upon the earlier of (i) the one-year anniversary of the date of grant or (ii) immediately prior to the annual meeting of the Issuer's stockholders that occurs following the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 23:07 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (Right to Buy) · Derivative | 8,425 | $0.00 Strike: $41.73 | $0.00 |
DisclosureSEC source: 0000950170-25-089667 · ownership.xml · derivative · entry 2 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,425 Underlying: Common Stock · 8,425 shares Expires 2035-06-19 F3 · derivative.exercise_date: One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 23:07 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantCommon Stock | 6,589 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-089667 · ownership.xml · nonDerivative · entry 1 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,589 F1 · kind: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. One-third of the RSUs will vest each year after June 20, 2025, such that all of the units will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:15 UTC | Biomea Fusion, Inc. BMEA · Entity 6606 | GrantStock Option (Right to Buy) · Derivative | 91,970 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0000950170-25-086191 · ownership.xml · derivative · entry 1 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,970 Underlying: Common Stock · 91,970 shares Expires 2035-06-10 F1 · derivative.exercise_date: The shares underlying the stock option will vest in full upon the earlier of (i) the one-year anniversary of the date of grant or (ii) immediately prior to the annual meeting of the Issuer's stockholders that occurs following the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date. Read SEC document |
| June 21, 2024 Filed Jun 25, 2024 21:34 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (Right to Buy) · Derivative | 26,014 | $0.00 Strike: $27.36 | $0.00 |
DisclosureSEC source: 0000950170-24-077437 · ownership.xml · derivative · entry 1 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,014 Underlying: Common Stock · 26,014 shares Expires 2034-06-20 F1 · derivative.exercise_date: One-third of the shares underlying the stock option will vest each year after June 21, 2024, such that all of the underlying shares will be vested on June 21, 2027, subject to the Reporting Person's continued service on the board of directors of the Issuer. Read SEC document |
| June 12, 2024 Filed Jun 13, 2024 20:30 UTC | Biomea Fusion, Inc. BMEA · Entity 6606 | GrantStock Option (Right to Buy) · Derivative | 51,025 | $0.00 Strike: $4.63 | $0.00 |
DisclosureSEC source: 0000950170-24-073068 · ownership.xml · derivative · entry 1 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,025 Underlying: Common Stock · 51,025 shares Expires 2034-06-11 F1 · derivative.exercise_date: The shares underlying the stock option will vest in full upon the earlier of (i) the one-year anniversary of the date of grant or (ii) immediately prior to the annual meeting of the Issuer's stockholders that occurs following the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 20:14 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (right to buy) · Derivative | 51,501 | $0.00 Strike: $16.75 | $0.00 |
DisclosureSEC source: 0001209191-23-039342 · doc4.xml · derivative · entry 1 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,501 Underlying: Common Stock · 51,501 shares Expires 2033-06-21 F1 · derivative.exercise_date: 1/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:00 UTC | Biomea Fusion, Inc. BMEA · Entity 6606 | GrantStock Option (Right to Buy) · Derivative | 6,989 | $0.00 Strike: $38.90 | $0.00 |
DisclosureSEC source: 0000950170-23-028668 · ownership.xml · derivative · entry 1 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,989 Underlying: Common Stock · 6,989 shares Expires 2033-06-13 F1 · derivative.exercise_date: The shares underlying the stock option will vest in full upon the earlier of (i) the one-year anniversary of the date of grant or (ii) immediately prior to the annual meeting of the Issuer's stockholders that occurs following the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date. Read SEC document |
| April 27, 2023 Filed May 1, 2023 20:14 UTC | Invitae Corp NVTA · Entity 95935 | GrantStock Option (right to buy) · Derivative | 28,901 | $0.00 Strike: $1.36 | $0.00 |
DisclosureSEC source: 0000899243-23-011928 · doc4.xml · derivative · entry 2 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,901 Underlying: Common Stock · 28,901 shares Expires 2033-04-27 F2 · derivative.exercise_date: Option vests in twelve equal monthly installments starting from April 27, 2023, subject to continued service with the Issuer through the applicable vesting dates. Read SEC document |
| April 27, 2023 Filed May 1, 2023 20:14 UTC | Invitae Corp NVTA · Entity 95935 | GrantCommon Stock | 70,422 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-011928 · doc4.xml · nonDerivative · entry 1 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,322 F1 · shares: Shares issuable upon settlement of a restricted stock unit award that vests in full on May 15, 2024, subject to continued service with the Issuer through the vesting date. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 20:23 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (right to buy) · Derivative | 104,921 | $0.00 Strike: $8.45 | $0.00 |
DisclosureSEC source: 0001209191-22-039225 · doc4.xml · derivative · entry 1 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,921 Underlying: Common Stock · 104,921 shares Expires 2032-06-22 F1 · derivative.exercise_date: 1/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the remaining underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on the June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 21:09 UTC | Biomea Fusion, Inc. BMEA · Entity 6606 | GrantStock Option (Right to Buy) · Derivative | 23,867 | $0.00 Strike: $10.20 | $0.00 |
DisclosureSEC source: 0000899243-22-024053 · doc4.xml · derivative · entry 1 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,867 Underlying: Common Stock · 23,867 shares Expires 2032-06-21 F1 · derivative.exercise_date: The shares underlying the stock option will vest in full upon the earlier of (i) the one-year anniversary of the date of grant or (ii) immediately prior to the annual meeting of the Issuer's stockholders that occurs following the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date. Read SEC document |
| April 28, 2022 Filed May 2, 2022 20:43 UTC | Invitae Corp NVTA · Entity 95935 | GrantStock Option (right to buy) · Derivative | 5,700 | $0.00 Strike: $5.22 | $0.00 |
DisclosureSEC source: 0000899243-22-016133 · doc4.xml · derivative · entry 4 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,700 Underlying: Common Stock · 5,700 shares Expires 2032-04-28 F2 · shares: Represents Board Chair compensation. F3 · derivative.exercise_date: Option vests in twelve equal monthly installments starting from April 28, 2022. Read SEC document |
| April 28, 2022 Filed May 2, 2022 20:43 UTC | Invitae Corp NVTA · Entity 95935 | GrantStock Option (right to buy) · Derivative | 16,100 | $0.00 Strike: $5.22 | $0.00 |
DisclosureSEC source: 0000899243-22-016133 · doc4.xml · derivative · entry 3 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,100 Underlying: Common Stock · 16,100 shares Expires 2032-04-28 F3 · derivative.exercise_date: Option vests in twelve equal monthly installments starting from April 28, 2022. Read SEC document |
| April 28, 2022 Filed May 2, 2022 20:43 UTC | Invitae Corp NVTA · Entity 95935 | GrantCommon Stock | 11,300 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-016133 · doc4.xml · nonDerivative · entry 2 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,900 F1 · shares: Shares issuable upon settlement of a restricted stock unit award that vests in full on May 15, 2023. F2 · shares: Represents Board Chair compensation. Read SEC document |
| April 28, 2022 Filed May 2, 2022 20:43 UTC | Invitae Corp NVTA · Entity 95935 | GrantCommon Stock | 32,100 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-016133 · doc4.xml · nonDerivative · entry 1 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,600 F1 · shares: Shares issuable upon settlement of a restricted stock unit award that vests in full on May 15, 2023. Read SEC document |
| June 17, 2021 Filed Jun 22, 2021 22:45 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (right to buy) · Derivative | 38,895 | $0.00 Strike: $62.63 | $0.00 |
DisclosureSEC source: 0000899243-21-025359 · doc4.xml · derivative · entry 1 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,895 Underlying: Common Stock · 38,895 shares Expires 2031-06-16 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in three annual installments after June 17, 2021, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such date. Read SEC document |
| April 30, 2021 Filed May 4, 2021 21:38 UTC | Invitae Corp NVTA · Entity 95935 | GrantStock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $34.90 | $0.00 |
DisclosureSEC source: 0000899243-21-018203 · doc4.xml · derivative · entry 4 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires 2031-04-30 F2 · shares: Represents Board Chair compensation. F3 · derivative.exercise_date: Option vests in twelve equal monthly installments starting from April 30, 2021. Read SEC document |
| April 30, 2021 Filed May 4, 2021 21:38 UTC | Invitae Corp NVTA · Entity 95935 | GrantStock Option (right to buy) · Derivative | 4,400 | $0.00 Strike: $34.90 | $0.00 |
DisclosureSEC source: 0000899243-21-018203 · doc4.xml · derivative · entry 3 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,400 Underlying: Common Stock · 4,400 shares Expires 2031-04-30 F3 · derivative.exercise_date: Option vests in twelve equal monthly installments starting from April 30, 2021. Read SEC document |
| April 30, 2021 Filed May 4, 2021 21:38 UTC | Invitae Corp NVTA · Entity 95935 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-018203 · doc4.xml · nonDerivative · entry 2 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,500 F1 · shares: Shares issuable upon settlement of a restricted stock unit award that vests in full on May 15, 2022. F2 · shares: Represents Board Chair compensation. Read SEC document |
| April 30, 2021 Filed May 4, 2021 21:38 UTC | Invitae Corp NVTA · Entity 95935 | GrantCommon Stock | 8,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-018203 · doc4.xml · nonDerivative · entry 1 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 F1 · shares: Shares issuable upon settlement of a restricted stock unit award that vests in full on May 15, 2022. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 23:52 UTC | Biomea Fusion, Inc. BMEA · Entity 6606 | GrantStock Option (Right to Buy) · Derivative | 28,911 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0000899243-21-016301 · doc4.xml · derivative · entry 1 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,911 Underlying: Common Stock · 28,911 shares Expires 2031-04-14 F1 · derivative.exercise_date: The shares underlying the stock option vest in equal monthly installments over a three year period beginning on April 20, 2021, so that all shares shall have vested on April 20, 2024, subject to the Reporting Person continued service to the Issuer through each vesting date. Read SEC document |
| December 16, 2020 Filed Dec 19, 2020 02:30 UTC | Invitae Corp NVTA · Entity 95935 | SaleCommon Stock | 3,600 | $51.47 | $185,280.12 |
DisclosureSEC source: 0000899243-20-034578 · doc4.xml · nonDerivative · entry 3 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: The sales of common stock were effected pursuant to a Rule 10b-5 sales plan adopted by the reporting person on August 7, 2020. F3 · price: Represents a weighted average sale price. Actual sale prices ranged from $51.33 to $51.81 per share. Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. Read SEC document |
| December 16, 2020 Filed Dec 19, 2020 02:30 UTC | Invitae Corp NVTA · Entity 95935 | SaleCommon Stock | 6,400 | $50.74 | $324,723.20 |
DisclosureSEC source: 0000899243-20-034578 · doc4.xml · nonDerivative · entry 2 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,600 F1 · shares: The sales of common stock were effected pursuant to a Rule 10b-5 sales plan adopted by the reporting person on August 7, 2020. F2 · price: Represents a weighted average sale price. Actual sale prices ranged from $50.30 to $51.29 per share. Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. Read SEC document |
| December 16, 2020 Filed Dec 19, 2020 02:30 UTC | Invitae Corp NVTA · Entity 95935 | Exercise / conversionCommon Stock | 10,000 | $24.16 | $241,600.00 |
DisclosureSEC source: 0000899243-20-034578 · doc4.xml · nonDerivative · entry 1 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 01:06 UTC | Invitae Corp NVTA · Entity 95935 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $11.13 | $0.00 |
DisclosureSEC source: 0001501134-20-000081 · wf-form4_160574794978058.xml · derivative · entry 8 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2027-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option was fully vested on May 2, 2018. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 01:06 UTC | Invitae Corp NVTA · Entity 95935 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $9.18 | $0.00 |
DisclosureSEC source: 0001501134-20-000081 · wf-form4_160574794978058.xml · derivative · entry 7 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2026-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option was fully vested on May 5, 2017. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 01:06 UTC | Invitae Corp NVTA · Entity 95935 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $8.51 | $0.00 |
DisclosureSEC source: 0001501134-20-000081 · wf-form4_160574794978058.xml · derivative · entry 6 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2025-11-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was fully vested on February 11, 2016. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 01:06 UTC | Invitae Corp NVTA · Entity 95935 | SaleCommon Stock | 7,117 | $47.05 | $334,854.85 |
DisclosureSEC source: 0001501134-20-000081 · wf-form4_160574794978058.xml · nonDerivative · entry 5 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales of common stock were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on August 7, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.82 to $47.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 01:06 UTC | Invitae Corp NVTA · Entity 95935 | SaleCommon Stock | 22,883 | $46.36 | $1,060,855.88 |
DisclosureSEC source: 0001501134-20-000081 · wf-form4_160574794978058.xml · nonDerivative · entry 4 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,117 F1 · kind: The sales of common stock were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on August 7, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.82 to $46.81, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 01:06 UTC | Invitae Corp NVTA · Entity 95935 | Exercise / conversionCommon Stock | 10,000 | $11.13 | $111,300.00 |
DisclosureSEC source: 0001501134-20-000081 · wf-form4_160574794978058.xml · nonDerivative · entry 3 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 01:06 UTC | Invitae Corp NVTA · Entity 95935 | Exercise / conversionCommon Stock | 10,000 | $9.18 | $91,800.00 |
DisclosureSEC source: 0001501134-20-000081 · wf-form4_160574794978058.xml · nonDerivative · entry 2 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 01:06 UTC | Invitae Corp NVTA · Entity 95935 | Exercise / conversionCommon Stock | 10,000 | $8.51 | $85,100.00 |
DisclosureSEC source: 0001501134-20-000081 · wf-form4_160574794978058.xml · nonDerivative · entry 1 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 15, 2020 Filed Jul 16, 2020 22:50 UTC | Invitae Corp NVTA · Entity 95935 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $8.08 | $0.00 |
DisclosureSEC source: 0000899243-20-019412 · doc4.xml · derivative · entry 4 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2028-06-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was fully vested on June 22, 2019. Read SEC document |
| July 15, 2020 Filed Jul 16, 2020 22:50 UTC | Invitae Corp NVTA · Entity 95935 | SaleCommon Stock | 6,829 | $34.24 | $233,814.03 |
DisclosureSEC source: 0000899243-20-019412 · doc4.xml · nonDerivative · entry 3 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: The sales of common stock were effected pursuant to a Rule 10b-5 sales plan adopted by the reporting person on August 8, 2019. F3 · price: Represents a weighted average sale price. Actual sale prices ranged from $33.77 to $34.55 per share. Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. Read SEC document |
| July 15, 2020 Filed Jul 16, 2020 22:50 UTC | Invitae Corp NVTA · Entity 95935 | SaleCommon Stock | 3,171 | $33.44 | $106,039.19 |
DisclosureSEC source: 0000899243-20-019412 · doc4.xml · nonDerivative · entry 2 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,829 F1 · shares: The sales of common stock were effected pursuant to a Rule 10b-5 sales plan adopted by the reporting person on August 8, 2019. F2 · price: Represents a weighted average sale price. Actual sale prices ranged from $32.76 to $33.75 per share. Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. Read SEC document |
| July 15, 2020 Filed Jul 16, 2020 22:50 UTC | Invitae Corp NVTA · Entity 95935 | Exercise / conversionCommon Stock | 10,000 | $8.08 | $80,800.00 |
DisclosureSEC source: 0000899243-20-019412 · doc4.xml · nonDerivative · entry 1 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 23:11 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (right to buy) · Derivative | 112,422 | $0.00 Strike: $29.00 | $0.00 |
DisclosureSEC source: 0000899243-20-015297 · doc4.xml · derivative · entry 1 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,422 Underlying: Common Stock · 112,422 shares Expires 2030-06-01 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in three annual installments after June 2, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such date. Read SEC document |
| May 27, 2020 Filed May 29, 2020 16:08 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | GrantStock Option (right to buy) · Derivative | 21,528 | $0.00 Strike: $48.51 | $0.00 |
DisclosureSEC source: 0000899243-20-014544 · doc4.xml · derivative · entry 1 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,528 Underlying: Common Stock · 21,528 shares Expires 2030-05-27 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in a single installment on the earlier of (i) the first anniversary of the grant date, so that all of the underlying shares shall be vested on May 26, 2021, or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service with the Issuer through the vesting date. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2018 Stock Option and Incentive Plan, as amended). Read SEC document |
| May 02, 2020 Filed Dec 19, 2020 02:30 UTC | Invitae Corp NVTA · Entity 95935 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $24.16 | $0.00 |
DisclosureSEC source: 0000899243-20-034578 · doc4.xml · derivative · entry 4 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2029-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was fully vested on May 2, 2020. Read SEC document |
| April 30, 2020 Filed May 2, 2020 00:41 UTC | Invitae Corp NVTA · Entity 95935 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $16.55 | $0.00 |
DisclosureSEC source: 0000899243-20-011775 · doc4.xml · derivative · entry 1 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-04-30 F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve equal monthly installments starting from April 30, 2020. Read SEC document |
| January 22, 2020 Filed Jan 24, 2020 18:43 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 771 | $0.00 Strike: $32.42 | $0.00 |
DisclosureSEC source: 0001562180-20-000570 · primarydocument.xml · derivative · entry 9 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 22,500 Underlying: Common Shares · 771 shares Expires 2028-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse. F9 · derivative.exercise_date: The option, representing a right to purchase a total of 30,000 shares was granted on November 20, 2018, vesting in four equal installments on November 20, 2019, 2020, 2021 and 2022, subject to the option holder's continuous service with the Issuer at each vesting date. The optionholder previously exercised the option with respect to 6,729 shares on November 20, 2019. F8 · ownership.nature: This employee stock option is held by the Reporting Person's spouse. Read SEC document |
| January 22, 2020 Filed Jan 24, 2020 18:43 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1,250 | $0.00 Strike: $37.54 | $0.00 |
DisclosureSEC source: 0001562180-20-000570 · primarydocument.xml · derivative · entry 8 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 2,500 Underlying: Common Shares · 1,250 shares Expires 2027-09-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse. F7 · derivative.exercise_date: The option, representing a right to purchase a total of 5,000 shares was granted on September 5, 2017, vesting in four equal installments on September 5, 2018, 2019, 2020 and 2021, subject to the option holder's continuous service with the Issuer at each vesting date. The optionholder previously exercised the option with respect to 1,250 shares on November 22, 2019. F8 · ownership.nature: This employee stock option is held by the Reporting Person's spouse. Read SEC document |
| January 22, 2020 Filed Jan 24, 2020 18:43 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 150 | $58.86 | $8,828.60 |
DisclosureSEC source: 0001562180-20-000570 · primarydocument.xml · nonDerivative · entry 7 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 1,250 F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.70 - $59.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| January 22, 2020 Filed Jan 24, 2020 18:43 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 200 | $58.00 | $11,599.00 |
DisclosureSEC source: 0001562180-20-000570 · primarydocument.xml · nonDerivative · entry 6 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 1,400 F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.70 - $58.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| January 22, 2020 Filed Jan 24, 2020 18:43 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 671 | $56.99 | $38,243.18 |
DisclosureSEC source: 0001562180-20-000570 · primarydocument.xml · nonDerivative · entry 5 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 1,600 F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.41 - $57.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| January 22, 2020 Filed Jan 24, 2020 18:43 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 500 | $55.99 | $27,995.50 |
DisclosureSEC source: 0001562180-20-000570 · primarydocument.xml · nonDerivative · entry 4 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 2,271 F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.39 - $56.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| January 22, 2020 Filed Jan 24, 2020 18:43 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 500 | $54.97 | $27,485.85 |
DisclosureSEC source: 0001562180-20-000570 · primarydocument.xml · nonDerivative · entry 3 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 2,771 F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.38 - $55.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.